Use of Enoxaparin with Corticosteroid Dexamethasone in the treatment of COVID-19 patients in Iraq
Keywords:
COVID-19 patients; Enoxaparin; Corticosteroid DexamethasoneAbstract
As of March 2022, more than 6 million people have died globally as a consequence of the extremely infectious viral disease produced by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), spread quickly around the world when the first instances of this mostly respiratory viral infection were initially recorded in Wuhan, Hubei Province, China, in late December 2019. As a result, the World Health Organization (WHO) was forced to declare it a worldwide pandemic on March 11, 2020. One of the most serious complication is cytokine storm which is term describe several disorders of immune dysfunction characterized by constitutional symptoms, systemic inflammation, and multiorgan dysfunction that can lead to multiorgan failure if inadequately treated. Aim of the study Comparison between inflammatory mediators in COVID 19 PATIENTS on dexamethasone and enoxaparin VS patients on dexamethasone only; Study the anti-inflammatory effects of enoxaparin; estimate the prognostic significance of IL6 & IL8 in COVID 19 patients. Methods: Total 70 iraqi patients with confirmed , severe COVID-19 infection admitted to RCU was done into two groups , 45 patients on dexamethasone and enoxaparin (group II ) and 25 patients on dexamethasone only ( group I ). blood sample from each group collected in the first day and seventh day of admission. Results: The levels of all studied parameters in patients received mono treatment of dexamethasone showed significant reduction in the levels of CRP and LDH and a significant increase in the level of lymphocytes in the seventh day comparing with the results obtained in the first day whereas all other parameters showed non-significant differences in their levels between the seventh and first day . Patients received a combination therapy of dexamethasone and Enoxaparin showed significant reduction in the levels of D-dimer, LDH, IL-6 and IL-8 with significant elevation in the levels of lymphocytes at the seventh day of treatment in comparison with the levels of these parameters in the first day. Conclusion Percentage of patients recovered after receiving the combination therapy were (73.3%) which is higher than that for patients receiving only dexamethasone. With interested correlation between treatment and the recovery of patients , the anti-inflammatory action of enoxaparin in addition to its anti-coagulant effect
Downloads
References
Singhal T. A review of coronavirus disease-2019 (COVID-19).
The indian journal of pediatrics. 2020 Apr;87(4):281-6.
Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R.
Features, evaluation, and treatment of coronavirus
(COVID-19). Statpearls [internet]. 2022 Feb 5.
Alsayed R, Ali AA, Makia R, Kadhom M, Raheem R, Al-Obaidi O,
Hadi A, Sabir DK, Yousif E. Challenges facing Iraq to tackle
the spread of COVID-19: An overview. Journal of university of
Anbar for Pure science. 2022 Feb 12;14(2):22-7.
Fajgenbaum DC, June CH. Cytokine storm. New England
Journal of Medicine. 2020 Dec 3;383(23):2255-73.
Tufan A, Guler AA, Matucci-Cerinic M. COVID-19, immune
system response, hyperinflammation and repurposing
antirheumatic drugs. Turkish journal of medical sciences.
O2O;5O(9):62O-32.
Kaiser R, Leunig A, Pekayvaz K, Popp O, Joppich M, Polewka
V, Escaig R, Anjum A, Hoffknecht ML, Gold C, Brambs S.
Self-sustaining IL-8 loops drive a prothrombotic
neutrophil phenotype in severe COVID-19. Jci Insight.
Sep 9;6(18).
Johns M, George S, Taburyanskaya M, Poon YK. A Review of
the Evidence for Corticosteroids in COVID-19. Journal of
pharmacy practice. 2022 Aug;35(4):626-37.
Saithong S, Saisorn W, Tovichayathamrong P, Filbertine G,
Torvorapanit P, Wright HL, Edwards SW,
Leelahavanichkul A, Hirankarn N, Chiewchengchol D.
Anti-Inflammatory Effects and Decreased Formation of
Neutrophil Extracellular Traps by Enoxaparin in COVID-
Patients. International journal of molecular sciences.
Apr 27;23(9):4805.
Debora L, Suprapti B, Kusumawati D, PS AD, Arini MN,
Aryanti LD. Analysis of Enoxaparin Effectiveness Based
on COVID-19 Severity: A Study in a Secondary Hospital
in Bandung, Indonesia. Indonesian Journal of
Pharmacy/Majalah Farmasi Indonesia. 2022 Jul 1;33(3).
Mousavi S, Moradi M, Khorshidahmad T, Motamedi M. Anti¬
inflammatory effects of heparin and its derivatives: a
systematic review. Advances in pharmacological
sciences. 2015 Oct;2015.
Drago F, Gozzo L, Li L, Stella A, Cosmi B. Use of enoxaparin to
counteract COVID-19 infection and reduce thromboembolic
venous complications: a review of the current evidence.
Frontiers in pharmacology. 2020 Sep16,'11:579886.
Vitiello A, Ferrara F. Low molecular weight heparin, antiinflammatory/immunoregulatory and antiviral effects, a short
update.Cardiovascular Drugsand Therapy.2021Aug 30:1-5.
Afsharirad B, Entezari-Maleki T. Enoxaparin s potential
mechanisms against SARS-CoV-2. International Journal
of Surgery. 2023 Jan 1;109(1):48-9.
Cardillo G, Viggiano GV, Russo V, Mangiacapra S, Cavalli A,
Castaldo G, Agrusta F, Bellizzi A, Amitrano M, lannuzzo
M, Sacco C. Antithrombotic and anti-inflammatory
effects of Fondaparinux and Enoxaparin in hospitalized
COVID-19 patients: the Fondenoxavid study. Journal of
blood medicine. 2021 Feb 11:69-75.
Upadhyay J, Tiwari N, Ansari MN. Role of inflammatory
markers in corona virus disease (COVID-19) patients: a
review. Experimental Biology and Medicine. 2020
Sep;245(15):1368-75.
Ghanem M, Brown SJ, Mohamed AE, Fuller HR. A meta¬
summary and bioinformatic analysis identified
interleukin 6 as a master regulator of COVID-19 severity
biomarkers. Cytokine. 2022 Aug 29:156011.
Talwar D, Kumar S, Acharya S, Raisinghani N, Madaan S,
Hulkoti V, Akhilesh A, Khanna S, Shah D, Nimkar S.
Interleukin 6 and its correlation with COVID-19 in terms
of outcomes in an intensive care unit of a rural hospital:
a cross-sectional study. Indian Journal of Critical Care
Medicine: Peer-reviewed, Official Publication of Indian
Society of Critical Care Medicine. 2022 Jan;26(1):39.
Downloads
Published
Issue
Section
License
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
